Vyro Bio Inc

Vyro Bio Inc. is a Brazilian biotechnology company founded in 2021 that specializes in the development of genetically engineered oncolytic viruses. The company utilizes a proprietary technology that modifies the Zika virus to selectively target and eliminate cancer stem cells found in malignant central nervous system tumors. By reprogramming the virus to specifically attack tumor cells while remaining safe for healthy neurons and tissues, Vyro aims to provide a targeted therapeutic approach. The technology leverages the virus's inherent ability to infect neural stem cells, which the company has repurposed to act as a therapeutic agent that both kills cancer cells and stimulates an anti-tumor immune response.

This innovative therapeutic platform addresses significant challenges in oncology, particularly for patients with difficult-to-treat brain tumors. By focusing on safety and precision, the company seeks to improve clinical outcomes and outperform conventional treatment options. Vyro is actively engaged in the scientific and regulatory ecosystem, having been selected for programs such as the CNPEM Deeptechs Acceleration Program and receiving regulatory guidance from Anvisa to support the development and future market access of its therapeutic solutions. The company originated from pioneering research conducted at the Human Genome and Stem Cell Research Center (HUG-CELL) at the University of São Paulo.